<DOC>
	<DOCNO>NCT02526641</DOCNO>
	<brief_summary>Investigation effect new Abbvie direct act anti-viral ( DAA ) treatment chronic viral hepatitis C infection macrophage specific activation marker soluble CD163 , portal hypertension determine hepatic venous pressure gradient ( HVPG ) , metabolic liver function determine galactose elimination capacity ( GEC ) test functional hepatic nitrogen clearance ( FHNC ) .</brief_summary>
	<brief_title>Macrophages , Portal Hypertension , Liver Function During AbbVie Treatment Chronic Hepatitis C</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Hypertension , Portal</mesh_term>
	<mesh_term>Liver Extracts</mesh_term>
	<criteria>Chronic hepatitis C genotype 1 4 patient initiate new AbbVie treatment ( paritaprevir , ritonavir , ombitasvir og dasabuvir sammen med ribavirin ) ChildPugh A liver cirrhosis Severe liver dysfunction ChildPugh klasse BC Life expectancy le 6 month plan liver transplantation TIPS procedure within 6 month noncompliance treatment study procedure allergy DAA drug use ( paritaprevir , ritonavir , ombitasvir , dasabuvir , ribavirin ) pregnancy expect pregnancy study ( anticonception use ) breast feed portal vein thrombosis liver cancer malignancy alcohol consumption</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Direct act antiviral treatment</keyword>
	<keyword>sCD163</keyword>
	<keyword>Portal hypertension</keyword>
	<keyword>Metabolic liver function</keyword>
	<keyword>Cirrhosis</keyword>
</DOC>